Phase 2 먹튀없는 바카라사이트 아톰카지노 data on the fatty liver reduction effect sparks a plan for a large-scale technology transfer contract this year
[by Ji, Yong Jun] D&D Pharmatech announced on June 4 that it completed the 'Database Lock' on May 21, a step that finalizes 먹튀없는 바카라사이트 아톰카지노 information and figures in preparation for analyzing the primary evaluation index results of the Phase 2 먹튀없는 바카라사이트 아톰카지노 trial of 'DD01 (development code),' a candidate treatment for Metabolic dysfunction-associated steatohepatitis (MASH) currently under development in the United States. Accordingly, data analysis is proceeding according to schedule, and the company anticipates confirming the primary evaluation index for the Phase 2 먹튀없는 바카라사이트 아톰카지노 trial by mid-June.
The ongoing Phase 2 clinical trial has been structured as a randomized, double-blind, placebo-controlled study involving 67 overweight or obese patients (BMI ≥ 25 ㎏/㎡) diagnosed with MASLD/MASH. Conducted at approximately 12 clinical sites in the United States, the trial will use MRI-PDFF to measure the 'proportion of patients experiencing a 30% reduction in liver fat' as the primary evaluation index at week 12. Additionally, a tissue biopsy will be conducted at week 48 to assess whether MASH has been resolved and liver fibrosis has improved, thereby securing crucial data for eventual approval by the U.S. Food and Drug Administration (FDA).
The company is currently in the process of conducting the 48-week treatment period for the Phase 2 먹튀없는 바카라사이트 아톰카지노 trial. Following the 12-week medication period, data for all enrolled patients have been compiled, and the 'database locked' has been completed. Statistical analysis by the contract research organization (CRO) is now underway, with the top-line results expected to be delivered to the company upon completion of the analysis. Given that the 먹튀없는 바카라사이트 아톰카지노 results at 12 weeks are the primary evaluation index, the company plans to disclose these results as soon as they are confirmed.
D&D Pharmatech analyzed the 12-week patient data for 50 individuals who were part of the Phase 2 먹튀없는 바카라사이트 아톰카지노 trial and had been assigned in a 1:1 ratio to the placebo and treatment groups. By the end of March, these patients were found to be 'undifferentiated between the placebo and treatment groups.' The company announced that 16 out of the 50 patients (estimated to be 23-26 in the treatment group) demonstrated a significant reduction in liver fat, by more than 70%. Given that the Phase 1 먹튀없는 바카라사이트 아톰카지노 trial demonstrated an average liver fat reduction of 50% in just four weeks of administration, the current findings indicate a very consistent efficacy profile, with heightened anticipation surrounding the primary 먹튀없는 바카라사이트 아톰카지노 evaluation index, which is expected to be announced this month.
In addition, as part of its preparations for the technology transfer and global partnering of DD01, the company recently entered into an agreement with a leading investment bank (IB) in the United States. Through this collaboration, the company is carrying out an objective value assessment and conducting preliminary contact to assess the competitiveness of DD01, thereby laying the groundwork for discussions with global pharmaceutical companies. The company expects that, following confirmation of the 12-week 먹튀없는 바카라사이트 아톰카지노 results of DD01, it will begin forming partnerships with the pharmaceutical companies with which it has been in preliminary contact.
D&D Pharmatech is currently making steady progress in the Phase 2 먹튀없는 바카라사이트 아톰카지노 trial of DD01. The upcoming announcement will focus on whether the primary evaluation indicator, pertaining to the reduction of hepatic steatosis at week 12, has been met. Concurrently, the ongoing 48-week treatment period, including tissue biopsies to verify compliance with MASH approval requirements, is advancing without additional adverse effects. The company anticipates concluding the 48-week treatment for all enrolled patients by year-end and plans to confirm and report key evaluation outcomes, such as fibrosis improvement based on tissue biopsy analysis, in the first half of 2026.
"As previous MASH clinical trials have consistently demonstrated a strong correlation between reductions in hepatic steatosis and improvements in fibrosis, as evidenced by tissue biopsy, the confirmation of a significant reduction in fatty liver at the 12-week primary endpoint is expected to underscore DD01’s competitiveness as a therapeutic agent, particularly with regard to fibrosis improvement," a D&D Pharmatech official said. "Given the ongoing large-scale transactions in the MASH sector by global pharmaceutical companies, we will make every effort to ensure the smooth execution of large-scale technology transfer agreements, supported by excellent clinical data, in collaboration with the investment bank (IB) with which we have recently signed a contract."